OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
2
Results
Show all
Save search
Copy query
Show results for
Unknown
(2)
Publication Date
Release Date
2025
(1)
2021
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion
via
integrin/BRAF/TAK1/ERK/ETV4 signaling.
Not available
S-EPMC9196059
|
biostudies-literature
Cite
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial.
Not available
S-EPMC12477293
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
